Locally Advanced Non-Small Cell Lung Cancer

Optimal Chemotherapeutic Agents and Duration

Research output: Contribution to journalReview article

Abstract

OPINION STATEMENT: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the USA. The treatment of locally advanced NSCLC (LA-NSCLC) is challenging and must be individualized. For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles is recommended. For patients with inoperable or unresectable stage III NSCLC, chemoradiation is the preferred treatment. Patients with a good performance status, minimal or no weight loss, and adequate pulmonary function should be offered concurrent chemoradiation. The optimal chemotherapeutic agents to be used concurrently with radiation remain undefined. In the USA, cisplatin plus etoposide or carboplatin plus paclitaxel are the most commonly used regimens. In addition, the optimal duration of therapy remains undefined, including the role of consolidation chemotherapy. Thus far, randomized phase III trials have failed to identify a survival advantage for administering chemotherapy beyond that delivered during radiation therapy. Molecularly targeted agents, angiogenesis inhibitors, and immunotherapy have a defined role for patients with metastatic disease. The role, if any, of these new classes of agents is undergoing investigation for patients with earlier stage disease, including stage III disease.

Original languageEnglish (US)
Pages (from-to)47
Number of pages1
JournalCurrent Treatment Options in Oncology
Volume16
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Cisplatin
Consolidation Chemotherapy
Drug Therapy
Angiogenesis Inhibitors
Carboplatin
Etoposide
Paclitaxel
Immunotherapy
Weight Loss
Radiotherapy
Therapeutics
Radiation
Lung
Survival
Mortality
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Locally Advanced Non-Small Cell Lung Cancer : Optimal Chemotherapeutic Agents and Duration. / Mamdani, Hirva; Jalal, Shadia I.; Hanna, Nasser.

In: Current Treatment Options in Oncology, Vol. 16, No. 10, 01.10.2015, p. 47.

Research output: Contribution to journalReview article

@article{0a4d490b55a949af99c27246619731ec,
title = "Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration",
abstract = "OPINION STATEMENT: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the USA. The treatment of locally advanced NSCLC (LA-NSCLC) is challenging and must be individualized. For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles is recommended. For patients with inoperable or unresectable stage III NSCLC, chemoradiation is the preferred treatment. Patients with a good performance status, minimal or no weight loss, and adequate pulmonary function should be offered concurrent chemoradiation. The optimal chemotherapeutic agents to be used concurrently with radiation remain undefined. In the USA, cisplatin plus etoposide or carboplatin plus paclitaxel are the most commonly used regimens. In addition, the optimal duration of therapy remains undefined, including the role of consolidation chemotherapy. Thus far, randomized phase III trials have failed to identify a survival advantage for administering chemotherapy beyond that delivered during radiation therapy. Molecularly targeted agents, angiogenesis inhibitors, and immunotherapy have a defined role for patients with metastatic disease. The role, if any, of these new classes of agents is undergoing investigation for patients with earlier stage disease, including stage III disease.",
author = "Hirva Mamdani and Jalal, {Shadia I.} and Nasser Hanna",
year = "2015",
month = "10",
day = "1",
doi = "10.1007/s11864-015-0364-2",
language = "English (US)",
volume = "16",
pages = "47",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Locally Advanced Non-Small Cell Lung Cancer

T2 - Optimal Chemotherapeutic Agents and Duration

AU - Mamdani, Hirva

AU - Jalal, Shadia I.

AU - Hanna, Nasser

PY - 2015/10/1

Y1 - 2015/10/1

N2 - OPINION STATEMENT: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the USA. The treatment of locally advanced NSCLC (LA-NSCLC) is challenging and must be individualized. For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles is recommended. For patients with inoperable or unresectable stage III NSCLC, chemoradiation is the preferred treatment. Patients with a good performance status, minimal or no weight loss, and adequate pulmonary function should be offered concurrent chemoradiation. The optimal chemotherapeutic agents to be used concurrently with radiation remain undefined. In the USA, cisplatin plus etoposide or carboplatin plus paclitaxel are the most commonly used regimens. In addition, the optimal duration of therapy remains undefined, including the role of consolidation chemotherapy. Thus far, randomized phase III trials have failed to identify a survival advantage for administering chemotherapy beyond that delivered during radiation therapy. Molecularly targeted agents, angiogenesis inhibitors, and immunotherapy have a defined role for patients with metastatic disease. The role, if any, of these new classes of agents is undergoing investigation for patients with earlier stage disease, including stage III disease.

AB - OPINION STATEMENT: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the USA. The treatment of locally advanced NSCLC (LA-NSCLC) is challenging and must be individualized. For patients with completely resected stage III NSCLC, adjuvant cisplatin-based chemotherapy for 4 cycles is recommended. For patients with inoperable or unresectable stage III NSCLC, chemoradiation is the preferred treatment. Patients with a good performance status, minimal or no weight loss, and adequate pulmonary function should be offered concurrent chemoradiation. The optimal chemotherapeutic agents to be used concurrently with radiation remain undefined. In the USA, cisplatin plus etoposide or carboplatin plus paclitaxel are the most commonly used regimens. In addition, the optimal duration of therapy remains undefined, including the role of consolidation chemotherapy. Thus far, randomized phase III trials have failed to identify a survival advantage for administering chemotherapy beyond that delivered during radiation therapy. Molecularly targeted agents, angiogenesis inhibitors, and immunotherapy have a defined role for patients with metastatic disease. The role, if any, of these new classes of agents is undergoing investigation for patients with earlier stage disease, including stage III disease.

UR - http://www.scopus.com/inward/record.url?scp=84979096285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979096285&partnerID=8YFLogxK

U2 - 10.1007/s11864-015-0364-2

DO - 10.1007/s11864-015-0364-2

M3 - Review article

VL - 16

SP - 47

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 10

ER -